CoChat

Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Interest in how the gut microbiome can influence the metabolic state of the host has recently heightened. One postulated link is bacterial fermentation of “indigestible” prebiotics to short-chain fatty acids (SCFAs), which in turn modulate the release of gut hormones controlling insulin release and appetite. We show here that SCFAs trigger secretion of the incretin hormone glucagon-like peptide (GLP)-1 from mixed colonic cultures in vitro. Quantitative PCR revealed enriched expression of the SCFA receptors ffar2 (grp43) and ffar3 (gpr41) in GLP-1–secreting L cells, and consistent with the reported coupling of GPR43 to Gq signaling pathways, SCFAs raised cytosolic Ca2+ in L cells in primary culture. Mice lacking ffar2 or ffar3 exhibited reduced SCFA-triggered GLP-1 secretion in vitro and in vivo and a parallel impairment of glucose tolerance. These results highlight SCFAs and their receptors as potential targets for the treatment of diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db11-1019

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. SCFAs stimulate GLP-1 secretion. A: Acute stimulation of GLP-1 secretion. Mixed primary cultures from murine colon were incubated for 2 h in 10 mmol/L glucose (Con) or in the additional presence of acetate (Ace) (1 mmol/L), propionate (Pro) (1 mmol/L), or butyrate (But) (1 mmol/L) with or without IBMX (100 μmol/L) as indicated. GLP-1 secretion in each well is expressed relative to the basal secretion (Con) measured in parallel on the same day. Data represent the means ± SEM of the number of wells indicated above each bar. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with their respective controls in the absence or presence of IBMX by one-way ANOVA with post hoc Dunnett test. B: GLP-1 secretion from primary colonic cultures triggered by 140 mmol/L cocktail of SCFAs and an osmotic control of 140 mmol/L NaCl. GLP-1 secretion in each well is expressed relative to the basal secretion measured in parallel on the same day. Data represent the means ± SEM of the number of wells indicated above each bar. **P < 0.01 and ***P < 0.001 compared with baseline and ##P < 0.01 compared with NaCl by Student t test.
FIG. 1. SCFAs stimulate GLP-1 secretion. A: Acute stimulation of GLP-1 secretion. Mixed primary cultures from murine colon were incubated for 2 h in 10 mmol/L glucose (Con) or in the additional presence of acetate (Ace) (1 mmol/L), propionate (Pro) (1 mmol/L), or butyrate (But) (1 mmol/L) with or without IBMX (100 μmol/L) as indicated. GLP-1 secretion in each well is expressed relative to the basal secretion (Con) measured in parallel on the same day. Data represent the means ± SEM of the number of wells indicated above each bar. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with their respective controls in the absence or presence of IBMX by one-way ANOVA with post hoc Dunnett test. B: GLP-1 secretion from primary colonic cultures triggered by 140 mmol/L cocktail of SCFAs and an osmotic control of 140 mmol/L NaCl. GLP-1 secretion in each well is expressed relative to the basal secretion measured in parallel on the same day. Data represent the means ± SEM of the number of wells indicated above each bar. **P < 0.01 and ***P < 0.001 compared with baseline and ##P < 0.01 compared with NaCl by Student t test.CC BY-NC-ND · PubMed Central
FIG. 2. SCFAs raise intracellular calcium in identified colonic L cells. A: Mixed colonic cultures were loaded with fura2-AM. Pseudocolor images of fura2 340:380 nm fluorescence ratio (reflecting [Ca2+]i) shown prior to (basal) and during the application of propionate (1 mmol/L), and after washing with saline. B: Identification of an L cell in the field of view shown in A identified by the fluorescence of Venus (475 nm excitation). C: A representative response of an L and a non–L cell recorded as in A. D: Mean calcium changes in L cells (filled bars) and non–L cells (open bars) after the addition of acetate (1 mmol/L), propionate (1 mmol/L), or CFMB (30 μmol/L) as indicated. Ratios (340:380) in the presence of the test agent were normalized to the mean of the background ratios of each cell measured before addition and after washout of the test compound. Data represent the means ± SEM of the number of cells indicated above each bar. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with baseline and ##P < 0.01 and ###P < 0.001 compared with non–L cells by Student t test. (A high-quality digital representation of this figure is available in the online issue.)
FIG. 2. SCFAs raise intracellular calcium in identified colonic L cells. A: Mixed colonic cultures were loaded with fura2-AM. Pseudocolor images of fura2 340:380 nm fluorescence ratio (reflecting [Ca2+]i) shown prior to (basal) and during the application of propionate (1 mmol/L), and after washing with saline. B: Identification of an L cell in the field of view shown in A identified by the fluorescence of Venus (475 nm excitation). C: A representative response of an L and a non–L cell recorded as in A. D: Mean calcium changes in L cells (filled bars) and non–L cells (open bars) after the addition of acetate (1 mmol/L), propionate (1 mmol/L), or CFMB (30 μmol/L) as indicated. Ratios (340:380) in the presence of the test agent were normalized to the mean of the background ratios of each cell measured before addition and after washout of the test compound. Data represent the means ± SEM of the number of cells indicated above each bar. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with baseline and ##P < 0.01 and ###P < 0.001 compared with non–L cells by Student t test. (A high-quality digital representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
FIG. 3. SCFA receptors FFAR2 and FFAR3 are expressed in L cells. Relative expression of ffar2 (A) and ffar3 (B) mRNAs relative to β-actin assessed by RT-PCR in FACS-sorted L cells and non–L cells from the small intestine (L+ and L−, respectively) and colon (LC+ and LC−) and the GLUTag model L-cell line. Data are presented as geometric means ± the upper SEM calculated from the log(base 2) data (n = 3 each). Significance comparisons between L cells and non–L cells were calculated by one-way ANOVA with a post hoc Bonferroni correction test performed on the log(base 2) data: *P < 0.05, **P < 0.01, and ***P < 0.001.
FIG. 3. SCFA receptors FFAR2 and FFAR3 are expressed in L cells. Relative expression of ffar2 (A) and ffar3 (B) mRNAs relative to β-actin assessed by RT-PCR in FACS-sorted L cells and non–L cells from the small intestine (L+ and L−, respectively) and colon (LC+ and LC−) and the GLUTag model L-cell line. Data are presented as geometric means ± the upper SEM calculated from the log(base 2) data (n = 3 each). Significance comparisons between L cells and non–L cells were calculated by one-way ANOVA with a post hoc Bonferroni correction test performed on the log(base 2) data: *P < 0.05, **P < 0.01, and ***P < 0.001.CC BY-NC-ND · PubMed Central
FIG. 4. Propionate (Prop) responses are not sensitive to pertussis toxin (Ptx). A: GLP-1 secretion from primary colonic cultures treated with IBMX (100 μmol/L) with or without somatostatin (Sst) (100 nmol/L) in the absence (■) or presence (□) of 0.2 μg/mL pertussis toxin (all n = 3). B: GLP-1 secretion from primary colonic cultures triggered by propionate (1 mmol/L) in the absence and presence of pertussis toxin (0.2 μg/mL). The number of wells is indicated above the bars. Mixed primary cultures from the colon were incubated in bath solution containing reagents as indicated. GLP-1 secretion in each well is expressed relative to the basal secretion (control), measured in parallel on the same day. Data represent the means ± SEM of the number of wells indicated. Statistical significance was assessed by one-way ANOVA with a post hoc Bonferroni correction test: *P < 0.05 and ***P < 0.001.
FIG. 4. Propionate (Prop) responses are not sensitive to pertussis toxin (Ptx). A: GLP-1 secretion from primary colonic cultures treated with IBMX (100 μmol/L) with or without somatostatin (Sst) (100 nmol/L) in the absence (■) or presence (□) of 0.2 μg/mL pertussis toxin (all n = 3). B: GLP-1 secretion from primary colonic cultures triggered by propionate (1 mmol/L) in the absence and presence of pertussis toxin (0.2 μg/mL). The number of wells is indicated above the bars. Mixed primary cultures from the colon were incubated in bath solution containing reagents as indicated. GLP-1 secretion in each well is expressed relative to the basal secretion (control), measured in parallel on the same day. Data represent the means ± SEM of the number of wells indicated. Statistical significance was assessed by one-way ANOVA with a post hoc Bonferroni correction test: *P < 0.05 and ***P < 0.001.CC BY-NC-ND · PubMed Central
FIG. 5. ffar2 and ffar3 knockout impairs SCFA-triggered GLP-1 secretion. A: GLP-1 secretion from primary colonic cultures from wild-type, ffar2−/−, and ffar3−/− mice. Mixed primary cultures from the colon from wild-type, ffar3−/−, and ffar2−/− mice were incubated in bath solution containing 10 mmol/L glucose together with acetate (1 mmol/L), propionate (1 mmol/L), and IBMX (100 μmol/L) as indicated (all n = 6). B: GLP-1 secretion from primary colonic cultures from wild-type, ffar2−/−, and ffar3−/− mice triggered by a 140 mmol/L cocktail of SCFAs and an osmotic control of 140 mmol/L NaCl. GLP-1 secretion in each well is expressed relative to the basal secretion (control) measured in parallel on the same day, and error bars represent 1 SEM. Effects of SCFAs in the absence (*P < 0.05, **P < 0.01, and ***P < 0.001) or presence (ΔΔP < 0.01 and ΔΔΔP < 0.001) of IBMX and effects of genotype (#P < 0.05, ##P < 0.01, and ###P < 0.001) were assessed for significance by two-way ANOVA with post hoc Bonferroni correction test. C–F: Expression of ffar3 (C), ffar2 (D), gcg (E), and pyy (F) mRNA in colonic tissue isolated from ffar3−/− (n = 5) and ffar2−/− (n = 5) mice and wild-type littermates (n = 6). Expression was normalized to that of β-actin in the same sample. Data are presented as geometric means, and the error bar was calculated from the log(base 2) data. Significance comparisons between genotypes were calculated by one-way ANOVA with a post hoc Dunnett test performed on the log(base 2) data: *P < 0.05 and ***P < 0.001. G: Content of active GLP-1 peptide in colonic tissue isolated from ffar3−/− and ffar2−/− mice and wild-type littermates. Active GLP-1 in colonic extracts was assessed by enzyme-linked immunosorbent assay and is expressed relative to sample protein assessed with a Bradford assay. Significance comparisons between genotypes (n = 6 each) were calculated by one-way ANOVA with a post hoc Dunnett test: *P < 0.05.
FIG. 5. ffar2 and ffar3 knockout impairs SCFA-triggered GLP-1 secretion. A: GLP-1 secretion from primary colonic cultures from wild-type, ffar2−/−, and ffar3−/− mice. Mixed primary cultures from the colon from wild-type, ffar3−/−, and ffar2−/− mice were incubated in bath solution containing 10 mmol/L glucose together with acetate (1 mmol/L), propionate (1 mmol/L), and IBMX (100 μmol/L) as indicated (all n = 6). B: GLP-1 secretion from primary colonic cultures from wild-type, ffar2−/−, and ffar3−/− mice triggered by a 140 mmol/L cocktail of SCFAs and an osmotic control of 140 mmol/L NaCl. GLP-1 secretion in each well is expressed relative to the basal secretion (control) measured in parallel on the same day, and error bars represent 1 SEM. Effects of SCFAs in the absence (*P < 0.05, **P < 0.01, and ***P < 0.001) or presence (ΔΔP < 0.01 and ΔΔΔP < 0.001) of IBMX and effects of genotype (#P < 0.05, ##P < 0.01, and ###P < 0.001) were assessed for significance by two-way ANOVA with post hoc Bonferroni correction test. C–F: Expression of ffar3 (C), ffar2 (D), gcg (E), and pyy (F) mRNA in colonic tissue isolated from ffar3−/− (n = 5) and ffar2−/− (n = 5) mice and wild-type littermates (n = 6). Expression was normalized to that of β-actin in the same sample. Data are presented as geometric means, and the error bar was calculated from the log(base 2) data. Significance comparisons between genotypes were calculated by one-way ANOVA with a post hoc Dunnett test performed on the log(base 2) data: *P < 0.05 and ***P < 0.001. G: Content of active GLP-1 peptide in colonic tissue isolated from ffar3−/− and ffar2−/− mice and wild-type littermates. Active GLP-1 in colonic extracts was assessed by enzyme-linked immunosorbent assay and is expressed relative to sample protein assessed with a Bradford assay. Significance comparisons between genotypes (n = 6 each) were calculated by one-way ANOVA with a post hoc Dunnett test: *P < 0.05.CC BY-NC-ND · PubMed Central
FIG. 6. ffar2 and ffar3 knockout mice have impaired glucose tolerance. A: Glucose stimulated GLP-1 secretion in vivo. ffar2−/− and ffar3−/− mice and wild-type littermates (n = 5 each) were dosed with DPP4 inhibitor at a dose of 20 mg/kg per os after a 4-h fast. Thirty minutes post–DPP4 inhibitor dosing, mice were dosed with 1.5 g/kg glucose per os Plasma active GLP-1 was assessed by a MesoScale assay at 0 and 30 min of the oral glucose tolerance test. Data represent means ± 1 SEM, and statistical significance was assessed by Student t test: *P < 0.05 and **P < 0.01. B–E: Oral glucose tolerance test in ffar2−/− mice (n = 8) (left panel) and wild-type littermates (n = 11) (B and D) or ffar3−/− mice (n = 7) (right panel) and wild-type littermates (n = 6) (C and E). Following an overnight fast, mice were given 1.5 g/kg glucose per os, and blood glucose (B and C) and insulin (D and E) were measured at the time points indicated. F and G: Insulin tolerance test in ffar2−/− mice (n = 11) (left panel) and wild-type littermates (n = 6) (F) or in ffar3−/− mice (n = 7) (right panel) and wild-type littermates (n = 7) (G). Following a 4-h fast, mice were given 0.75/kg insulin intraperitoneal, and blood glucose was measured at the time points indicated. No significant differences between genotypes were observed. Data in B–G represent means ± 1 SEM, and statistical significance was assessed by two-way ANOVA with repeated measures: * P < 0.05, ** P < 0.01, and *** P < 0.001.
FIG. 6. ffar2 and ffar3 knockout mice have impaired glucose tolerance. A: Glucose stimulated GLP-1 secretion in vivo. ffar2−/− and ffar3−/− mice and wild-type littermates (n = 5 each) were dosed with DPP4 inhibitor at a dose of 20 mg/kg per os after a 4-h fast. Thirty minutes post–DPP4 inhibitor dosing, mice were dosed with 1.5 g/kg glucose per os Plasma active GLP-1 was assessed by a MesoScale assay at 0 and 30 min of the oral glucose tolerance test. Data represent means ± 1 SEM, and statistical significance was assessed by Student t test: *P < 0.05 and **P < 0.01. B–E: Oral glucose tolerance test in ffar2−/− mice (n = 8) (left panel) and wild-type littermates (n = 11) (B and D) or ffar3−/− mice (n = 7) (right panel) and wild-type littermates (n = 6) (C and E). Following an overnight fast, mice were given 1.5 g/kg glucose per os, and blood glucose (B and C) and insulin (D and E) were measured at the time points indicated. F and G: Insulin tolerance test in ffar2−/− mice (n = 11) (left panel) and wild-type littermates (n = 6) (F) or in ffar3−/− mice (n = 7) (right panel) and wild-type littermates (n = 7) (G). Following a 4-h fast, mice were given 0.75/kg insulin intraperitoneal, and blood glucose was measured at the time points indicated. No significant differences between genotypes were observed. Data in B–G represent means ± 1 SEM, and statistical significance was assessed by two-way ANOVA with repeated measures: * P < 0.05, ** P < 0.01, and *** P < 0.001.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

Items 401–500 of 1,015

Metadata

Authors
Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M.
Affiliations
  • Addenbrooke's Hospital (GB)
  • Takeda (United Kingdom) (GB)
Corresponding author
  • Reimann, Frank
  • Gribble, Fiona M.
Venue
Diabetes
Published
2012-01-17
Volume
61
Issue
2
Pages
364-371
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2168842536
Cited by
2,404
References
32
Citations by year
2026: 266 · 2025: 233 · 2024: 203 · 2023: 183 · 2022: 245 · 2021: 205 · 2020: 215 · 2019: 151 · 2018: 158 · 2017: 120 · 2016: 132 · 2015: 103 · 2014: 92 · 2013: 65 · 2012: 27
FWCI
49.00
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
  • Apollo
Funders
  • Wellcome Trust (084210/Z/07/Z, 088357/Z/09/Z, #WT084210, 088357, 088357/Z/09/A)
  • European Commission (2007–2013, 266408)
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
short-chain fatty acids, glucagon-like peptide-1, FFAR2, GPR43, GPR41, incretin secretion, gut microbiota, prebiotic fermentation, colonic epithelial cells, calcium signaling, glucose tolerance, diabetes treatment, Gq signaling
MeSH terms
Animals, Calcium, Colon, Fatty Acids, Volatile, Mice, Inbred C57BL, Signal Transduction, GTP-Binding Protein alpha Subunits, Gi-Go, Receptors, G-Protein-Coupled, Mice, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.